[Nedaplatin and etoposide combination chemotherapy in a patient with small cell carcinoma undergoing hemodialysis].
A 61-year-old man with chronic renal failure caused by polycystic kidney disease requiring hemodialysis three times weekly developed small cell carcinoma of the lung. The patient received combination chemotherapy with nedaplatin (50 mg) and etoposide (50 mg). Blood levels were monitored, showing that nedaplatin was more dialyzable than cisplatin. The patient achieved a complete response. These results suggest that nedaplatin-etoposide combination chemotherapy may be safer than cisplatin-containing regimen for patients with chronic renal failure hemodialysis and that a satisfactory response can be expected.
Nishioka
Y
Y
5th Dept. of Internal Medicine, Hyogo College of Medicine.
Kitada
O
O
Meguro
T
T
Aragane
K
K
Tanimukai
T
T
Nakamura
H
H
Nakahama
H
H
Matsuyama
T
T
Sugita
M
M
Yano
T
T
Takenaka
Y
Y
Takamitsu
Y
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D012074:Remission Induction; D006435:Renal Dialysis
D009944:Organoplatinum Compounds; D005047:Etoposide; C053989:nedaplatin